Home / Health / Roche Drug Slashes Body Weight by 22.7% in Trials
Roche Drug Slashes Body Weight by 22.7% in Trials
6 Jun
Summary
- Roche's experimental obesity drug achieved 22.7% weight loss in mid-stage trials.
- Over a quarter of patients on the highest dose lost at least 30% of their body weight.
- The drug mimics GLP-1 and GIP hormones, showing no plateau in weight loss at 48 weeks.
A mid-stage trial for Roche's experimental obesity drug, enicepatide, revealed an average body weight loss of 22.7% among patients after 48 weeks. A striking finding was that over a quarter of individuals administered the highest dosage achieved a weight reduction of 30% or more.
This once-weekly injectable drug mimics both GLP-1 and GIP hormones. Trial data indicated no plateau in weight loss at the 48-week mark, suggesting continued efficacy if treatment extends beyond the study's duration. Roche is competing in a burgeoning obesity market projected to exceed $100 billion annually.
Adverse events, primarily mild to moderate gastrointestinal issues, led to treatment discontinuations in 5.9% of patients on enicepatide, compared to 1.3% in the placebo group. The study involved 469 adults and presented clear dose-response findings at the American Diabetes Association meeting.
